Hyderabad: Acubiosys Private Limited, a biotechnology startup incubated at CDFD Technology Incubator, which is the business incubator of BRIC-Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD) in Hyderabad, is advancing next-generation healthcare solutions for autoimmune diseases, skin disorders, and chronic wound management by integrating Artificial Intelligence (AI), nanotechnology, and advanced biomedical research.
Acubiosys has been supported by CDFD Technology Incubator through access to state-of-the-art laboratory infrastructure, mentorship, industry and investor networking, and a vibrant innovation ecosystem.
The startup is focused on developing evidence-based natural and synthetic therapeutics for conditions such as psoriasis, atopic dermatitis, and diabetic foot ulcers. By combining AI-assisted drug discovery, nanotechnology-enabled formulation development, and rigorous laboratory validation, Acubiosys aims to accelerate the development of safer, more effective, and targeted therapies that address unmet clinical needs.
The company has successfully developed and commercialized two innovative products manufactured in India under AYUSH regulatory compliance and Good Manufacturing Practices (GMP) standards
BOCUGL – A patented AI driven and nanotechnology-based topical formulation designed for the management of Psoriasis, Atopic dermatitis, and Melasma
AZBECO – A patented AI driven advanced wound care formulation developed using nanotechnology to promote faster healing of chronic wounds and diabetic foot ulcers.
The underlying technologies and formulations have been the subject of patent applications in India, China, and the United States, reflecting the company’s commitment to innovation, strengthening its global intellectual property portfolio, and demonstrating the commercial potential of its technologies.
Building on these achievements, Acubiosys is expanding its research pipeline through AIdriven therapeutic discovery platforms that integrate computational biology, biomarker analysis, and experimental validation to identify next-generation phytopharmaceuticals and precision medicine candidates for autoimmune and infectious diseases.
Dr. Srinivas Maddi, Founder and CEO of Acubiosys Private Limited, said, “Our vision is to bridge artificial intelligence, nanotechnology, and life sciences to develop affordable, science-backed healthcare solutions that address unmet medical needs. By combining cutting-edge research with translational innovation, we aim to deliver accessible therapies that improve patient outcomes while contributing to India’s growing biotechnology ecosystem.
Leveraging the world-class R&D facilities available at CDFD Technology Incubator, we were able to undertake critical preclinical studies, including animal studies, enabling the validation and advancement of our technology. The incubator also facilitated strategic guidance, regulatory support, and collaborations that have helped accelerate our translational research and commercialization journey.”
With a strong emphasis on innovation, translational research, and commercialization, Acubiosys is committed to developing high-quality, intellectual property-driven healthcare solutions while strengthening India’s biotechnology ecosystem and improving the quality of life for patients worldwide.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: deccanchronicle.com
